Summary & Overview
HCPCS Q4324: Amniotic membrane application, per square centimeter
HCPCS Level II code Q4324 denotes an add-on billing unit for amniotic membrane application billed per square centimeter, used as an adjunct in surgical or procedural repair where biologic grafting is employed. This code matters nationally because it standardizes reporting and billing for a growing class of biologic graft materials used across ophthalmology, wound care, and reconstructive procedures, enabling clearer tracking of utilization and costs associated with these products.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical role and service context, payer coverage landscape, common billing modifiers, and implications for procedure coding and claims processing. The publication outlines benchmarks and coding considerations relevant to providers and billing teams, summarizes typical sites of service, and highlights areas where policy updates or payer-specific rules may affect reimbursement and documentation requirements.
This summary is written for a national audience and is intended to inform clinicians, coding professionals, and policy analysts about the administrative and clinical context of HCPCS Level II code Q4324. Data not available in the input is noted where applicable in detailed sections.
Billing Code Overview
HCPCS Level II code Q4324 describes Amniotx, per square centimeter (add-on, list separately in addition to primary procedure). This code represents an add-on product or procedure used in amniotic membrane transplantation or application measured per square centimeter.
-
Service type: Surgical adjunct or biologic graft application
-
Typical site of service: Operating room or ambulatory surgical center where transplant or grafting procedures are performed
Clinical & Coding Specifications
Clinical Context
A patient with a chronic non-healing surgical wound or an acute soft-tissue defect undergoes application of amniotic membrane product as an adjunctive therapy. Typical patients are adults with diabetic foot ulcers, venous stasis ulcers, or complex surgical wounds that have failed standard care. The clinical workflow begins with wound assessment and documentation of wound dimensions. The provider measures the wound surface area in square centimeters and determines the number of amniotic membrane units required. A primary procedure—such as debridement, incision and drainage, or wound repair—is performed first. The amniotic product is then trimmed to fit the wound bed and applied directly to the wound surface, often secured with appropriate dressings and, when applicable, secondary sutures or adhesives. Post-application instructions include offloading, infection surveillance, dressing changes, and scheduled follow-up visits to assess graft take and healing progression.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard reporting when no modifier applies to the service |
22 | Increased procedural service | Use when work, time, or effort required for the amniotic application is substantially greater than typically required |